Datopotamab deruxtecan

AbbVie's $9B neuroscience bet falters, AstraZeneca resubmits lung cancer drug, 23andMe halts drug development, ALS startup Trace Neurosciences raises $101M, Neurogene's gene therapy faces severe side effect, Pfizer explores wearables in drug trials.

Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for Enhertu, a HER2-directed ADC. Enhertu, developed jointly, is transforming HER2+ solid tumour treatment. The Galien Foundation recognizes impactful FDA-approved treatments, honoring medical innovation.

ESMO 2024 Congress featured updates on ovarian, cervical, and endometrial cancers, including niraparib's long-term PFS benefit, gotistobart's potential in platinum-resistant disease, and T-DXd's tumor-agnostic approval. Checkpoint inhibitors are integrating into cervical and endometrial cancer treatments, with clinical trials showing benefits in PFS and OS. ADCs like tisotumab vedotin and TROP2-directed ADCs are emerging as therapeutic options, particularly in endometrial cancer.

2024 NSCLC highlights: osimertinib sets new standard for EGFR-mutant, unresectable stage III disease; lorlatinib offers unprecedented PFS in ALK-positive tumors; perioperative nivolumab improves EFS over neoadjuvant-only; novel agents enhance neoadjuvant durvalumab efficacy.

Daiichi Sankyo and AstraZeneca launch three Phase III trials to assess datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous NSCLC, involving rilvegostomig, osimertinib, and chemotherapy.

Datopotamab deruxtecan, a TROP2-directed ADC developed by Daiichi Sankyo and AstraZeneca, is being tested in three phase 3 trials for nonsquamous non-small cell lung cancer. The trials aim to evaluate its efficacy in combination with targeted treatments or immunotherapies, with primary endpoints focusing on progression-free survival and overall survival.

Three phase 3 trials initiated for datopotamab deruxtecan-based combinations in advanced nonsquamous non-small cell lung cancer patients, evaluating efficacy and safety.

Emerging therapies for bladder cancer include erdafitinib, enfortumab vedotin, and pembrolizumab. Key studies highlight genomic heterogeneity, biomarker guidance, and immunotherapy responses. Precision oncology faces challenges with clonal evolution and resistance mechanisms. Future directions focus on improving biomarker-driven trials and understanding tumor immune microenvironments.

Gilead withdraws Trodelvy for bladder cancer after negative trial results, impacting less than 10% of sales; focuses on breast cancer, with $1 billion sales forecast by 2030; faces challenges in lung cancer expansion; awaits Phase 3 trial data for triple-negative breast cancer.

Oncology dominates pharmaceutical innovation, with 1,600 cancer drugs in development. Spending on cancer drugs is projected to reach $409 billion by 2028, with high costs for novel agents. Biosimilars and generics may provide savings but cannot match rising expenditures. The focus is shifting towards cell therapies for solid tumors, with 44% of trials initiated in 2023 targeting solid tumor indications. Several cancer drugs have been approved by the FDA this year, and many more are expected to receive approval decisions soon.